Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 195-206

  Traxler, Peter ^a   Furet, Pascal ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ATP competitive inhibitors; Epidermal growth factor receptor tyrosine kinase; Pharmacophore model; Platelet derived growth factor receptor tyrosine kinase; Protein tyrosine kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADENOSINE TRIPHOSPHATE; ANILINE DERIVATIVE; CGP 59326; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; IMATINIB; ISOFLAVONE DERIVATIVE; LEFLUNOMIDE; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; SEMAXANIB; UNCLASSIFIED DRUG;

BINDING SITE; CANCER; CONFERENCE PAPER; DOWN REGULATION; DRUG DESIGN; ENZYME INHIBITION; HUMAN; MODEL; NONHUMAN; ONCOGENE C FOS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS; RESTENOSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG DESIGN; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MODELS, STRUCTURAL; MOLECULAR STRUCTURE; PHOSPHOTRANSFERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0033026444     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00044-8     Document Type: Conference Paper

References (37)

1. r l90,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP 57148). Clin. Cancer Res. 4:1998;1661-1672.
2. Bridges A.J. The current status of tyrosine kinase inhibitors. do the diarylamine inhibitors of the EGF receptor represent a new beginning? Exp. Opin. Ther. Patents. 5:1995;1245-1257.
3. Buchdunger E., Zimmermann J., Mett H., Meyer T., Müller M., Druker B.J., Lydon N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
4. Burke T.R. Protein-tyrosine kinase inhibitors. Drugs Future. 17:1992;119-131.
5. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N., Gilliland D.G., Druker B.J. CGP 57148B, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 90:1997;4947-4952.
6. Deininger M.W., Goldman J.M., Lydon N., Melo J.V. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of Bcr-Abl-positive cells. Blood. 90:1997;3691-3698.
7. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2:1996;561-566.
8. Filgueira de Azevedo W. Jr., Mueller-Dieckmann H.J., Schulze-Gahmen U., Worland P.J., Sausville E., Kim S.-H. Structural basis for specificity and potency of a flavanoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 93:1996;2735-2740.
9. Fry D.W. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs. 3:1994;577-595.
10. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
11. Furet P., Caravatti G., Lydon N., Priestle J., Sowadski J., Trinks U., Traxler P. Modeling study of protein kinase inhibitors. binding mode of staurosporine - origin of the selectivity of CGP 52411 J. Comput. Aided Mol. Des. 9:1995;465-471.
12. + leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23:1997;380-394.
13. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271:1996;695-701.
14. Hodge C.N., Pierce J.A. A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase. Bioorg. Med. Chem. Lett. 3:1993;1605-1608.
15. Lawie A.M., Noble M.E.M., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Struct. Biol. 4:1997;796-801.
16. Levitzky A., Gazit A. Tyrosine kinase inhibition. an approach to drug development Science. 267:1995;1782-1788.
17. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-959.
18. Palmer B.D., Trumpp-Kallmeyer S., Fry D.W., Nelson J.M., Showalter H.D.H., Denny W.A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors. synthesis, biological evaluation, and modeling of the mode of binding J. Med. Chem. 40:1997;1519-1529.
19. Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H., Cody D.R., McMichael A., Fry D.W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-(phenylmethyl-amino)- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 38:1995;3482-3487.
20. Rewcastle G.W., Palmer B.D., Thompson A.M., Bridges A.J., Cody D.R., Zhou H., Fry D.W., McMichael A., Kraker A.J., Denny W.A. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]-pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 39:1996;1823-1835.
21. Rewcastle G.W., Bridges A.J., Fry D.W., Rubin J.A., Denny W.A. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted-4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 40:1997;1820-1826.
22. Schulze-Gahmen U., Brandsen J., Jones H.D., Morgan D.O., Meijer L., Vesely J., Kim S.H. Multiple modes of ligand recognition. crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine Proteins. 22:1995;378-391.
23. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
24. Spada A.P., Myers M.R. Small molecule inhibitors of tyrosine kinase activity. Exp. Opin. Ther. Patents. 5:1995;805-817.
25. Thompson A.M., Bridges A.J., Fry D.W., Kraker A.J., Denny W.A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-(phenyl-methyl)amino-pyrido[4,3-d]pyrimidines. a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor J. Med. Chem. 38:1995;3780-3788.
26. Traxler P. Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Patents. 7:1997;571-588.
27. Traxler, P. (1998) Protein tyrosine kinase inhibitors in cancer treatment (part II). Exp. Opin. Ther. Patents.
28. Traxler P., Green J., Mett H., Séquin U., Furet P. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors. isoflavones and 3-phenyl-4(1H)-quinolones J. Med. Chem. in press:1999.
29. Traxler P., Lydon N. Recent advances in protein tyrosine kinase inhibitors. Drugs Future. 20:1995;1261-1274.
30. Traxler P., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. 4-(Phenylamino)pyrrolopyrimidines. potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 38:1996;2285-2292.
31. Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors. 4-(phenylamino)pyrazolo-pyrimidines J. Med. Chem. 40:1997;3601-3616.
32. Traxler, P., Bold, G., Buchdunger, E., Lang, M., Mett, H. and Furet, P. (1998) The use of a pharmacophore model for the design of potent and selective EGFR tyrosine kinase inhibitors. In: 215th American Chemical Society National Meeting, Dallas, TX, 29 March-2 April, Lecture, Medi 104.
33. Trumpp-Kallmeyer S., Rubin J.R., Humblet C., Hamby J.M., Showalter H.D.H. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J. Med. Chem. 41:1998;1752-1763.
34. Ward W.H.J., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Green L.R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48:1994;659-666.
35. Zheng J., Knighton D.R., Ten Eyck L.F., Karlsson R., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase vomplexed with MgATP and peptide inhibitor. Biochemistry. 32:1993;2154-2161.
36. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N., Traxler P. Phenylamino-pyrimidine (PAP)-derivatives. a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors Bioorg. Med. Chem. Lett. 6:1996;1221-1226.
37. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N. Potent and selective inhibitors of the Abl-kinase. phenylaminopyrimidine (PAP)-derivatives Biorg. Med. Chem. Lett. 7:1997;187-192.